Drugmakers' dustbins are filled with failed attempts to slow the progression of Alzheimer's disease, yet drug developers, including Biogen (NASDAQ:BIIB), remain undaunted in their pursuit of new treatments. Recently, Biogen reported data from a midstage trial that suggests it could be rewarded for its perseverance.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,